Bluejay Diagnostics (BJDX) AI Stock Analysis

• Market Cap: $1.81M
• Dividend Yield: N/A
• Average Volume (3M): 5.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.32
• Revenue Growth: N/A
• EPS Growth: 97.70%
• Country: US
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): N/A
• Shares Outstanding: 972,000
• 10 Day Avg. Volume: 15,571,172
• 30 Day Avg. Volume: 5,266,425
• PEG Ratio: <0.01
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.19
• Enterprise Value/Market Cap: -2.32
• Enterprise Value/Revenue: -19.44
• Enterprise Value/Gross Profit: 303.79
• Enterprise Value/Ebitda: 0.62
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $2.00 ▲(207.69% Upside)
• Action: Reiterated Date: 03/07/26
• Date: Action: Reiterated 03/07/26

The score is held down primarily by very weak financial performance (minimal revenue, ongoing losses, and sustained cash burn) and a bearish technical setup below key moving averages. Positive corporate developments in clinical progress and manufacturing readiness provide some offset, but they do not yet translate into proven revenue traction or profitability.

Positive Factors

Clinical Trial Progress

Broad enrollment progress toward a 750-patient target materially reduces clinical execution risk and bolsters the dataset for regulatory engagement. Sustained, protocol-compliant enrollment improves the odds of a defensible regulatory submission and accelerates transition from trial to commercialization planning.

Manufacturing Readiness

Owning commercial-scale antibody production and inventory to support millions of cartridges materially lowers supply-chain and COGS execution risk. This capability supports scalable manufacture, reduces dependence on external suppliers, and is a durable operational asset for commercial roll-out of the Symphony platform.

Low Leverage

Minimal debt reduces bankruptcy and interest-coverage risk, preserving strategic flexibility. A positive equity base—despite erosion—gives the company capacity to raise incremental capital or execute strategic partnerships without being over-levered, which is beneficial during a multi-stage commercialization path.

Negative Factors

Persistent Cash Burn

Sustained negative operating and free cash flow creates ongoing funding needs that can force dilutive financings or constrain commercialization investments. Persistent cash burn is a structural risk until revenue scales, increasing reliance on external capital and limiting nimbleness in commercialization and regulatory activities.

Lack of Revenue Traction

Absent meaningful revenue and repeated net losses imply the company has yet to validate market demand or pricing at scale. This weak earnings quality makes the business dependent on successful regulatory approval and adoption, lengthening the path to sustainable margins and cash generation.

Warrant Overhang & Dilution Risk

Significant outstanding cash-exercisable warrants create potential share dilution and capital structure uncertainty. If exercised, the inflow depends on market conditions; if not, they represent an overhang that complicates planning and could pressure future financing terms or ownership percentages during critical commercialization stages.

Bluejay Diagnostics Business Overview & Revenue Model

Company Description

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Bluejay Diagnostics generates revenue through the sale of its Symphony System and associated consumables. The Symphony System is marketed to hospitals, clinics, and other healthcare facilities that require rapid diagnostic testing capabilities. The company may also engage in partnerships or collaborations with other healthcare entities to expand the reach and application of its technology. Additionally, Bluejay may generate revenue from licensing its technology or entering into strategic alliances with larger diagnostic or healthcare companies. These key revenue streams, along with potential government or institutional contracts, contribute to the company's overall earnings.

Bluejay Diagnostics Financial Statement Overview

Summary

Financial execution risk remains high: revenue is effectively absent and profitability is deeply negative with multi-million-dollar net losses and persistent cash burn. Offsetting factors are low leverage and a still-positive equity base, plus some narrowing of losses and cash outflows versus prior years.

Income Statement

Operating performance remains very weak. Revenue is effectively absent in most years (including 2023–2025), with a sharp decline shown in 2025, and profitability is deeply negative with continued multi-million-dollar net losses (2025 net loss of ~$6.8M; 2024 net loss of ~$7.7M). A positive is that losses have narrowed versus 2022–2023, indicating some cost control progress, but the lack of meaningful revenue traction keeps earnings quality and business momentum poor.

Balance Sheet

Leverage is low, which reduces financial risk (2025 debt-to-equity ~0.02; total debt ~$0.12M). The company also has positive equity in recent years (2023–2025), suggesting balance sheet repair versus 2020 when equity was negative. However, equity has declined substantially from 2021 levels and returns on equity are strongly negative, reflecting that ongoing losses are eroding the capital base over time.

Cash Flow

Cash generation is consistently negative, with sizable ongoing cash burn (2025 operating cash flow about -$6.1M; free cash flow about -$6.2M). There is some improvement versus 2024 as cash outflows narrowed, but free cash flow remains persistently negative and growth in free cash flow has been volatile across years, highlighting funding dependence until revenues scale.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	216.09K	0.00	0.00	0.00	249.04K	0.00
Gross Profit	-13.83K	0.00	-199.10K	-780.96K	48.91K	-145.72K
EBITDA	-6.74M	0.00	-6.70M	-9.17M	-9.01M	-3.08M
Net Income	-6.85M	-6.85M	-7.72M	-9.95M	-9.30M	-3.73M
Balance Sheet
Total Assets	4.89M	7.12M	6.66M	4.87M	13.52M	21.02M
Cash, Cash Equivalents and Short-Term Investments	3.08M	5.16M	4.30M	2.21M	10.11M	19.05M
Total Debt	142.99K	120.21K	222.25K	352.98K	492.62K	0.00
Total Liabilities	1.20M	1.14M	927.92K	1.97M	1.98M	637.16K
Stockholders Equity	3.69M	5.98M	5.73M	2.89M	11.54M	20.38M
Cash Flow
Free Cash Flow	-6.34M	-6.23M	-8.13M	-9.02M	-8.94M	-4.39M
Operating Cash Flow	-6.34M	-6.05M	-7.82M	-8.31M	-7.74M	-4.37M
Investing Cash Flow	-1.13K	-173.74K	-306.78K	-704.17K	-1.20M	-23.95K
Financing Cash Flow	3.67M	7.09M	10.22M	1.11M	8.07K	22.53M

Bluejay Diagnostics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BJDX, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 2.36, below the 50-day MA of 2.70, and below the 200-day MA of 5.59, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 30.21 is Neutral, neither overbought nor oversold. The STOCH value of 29.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BJDX.

Bluejay Diagnostics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BJDX	46 Neutral	$1.81M	-0.18	-126.20%	―	―	97.70%
TIVC	45 Neutral	$2.16M	-0.37	-178.18%	―	-49.63%	82.22%
AEMD	44 Neutral	$2.24M	-0.28	-191.39%	―	―	76.53%
VERO	41 Neutral	$725.06K	-0.05	-854.61%	―	-12.39%	44.61%
DHAI	37 Underperform	$5.23K	-0.95	―	―	―	―

Bluejay Diagnostics Corporate Events

Bluejay Diagnostics Completes Warrant Exercises, Clarifies Capital Structure

On February 20, 2026, Bluejay Diagnostics announced that all prefunded warrants issued in its October 2025 private placement had been fully exercised as of February 19, 2026, leaving no prefunded warrants of any class outstanding. Following these exercises, the company reported approximately 972,000 shares of common stock outstanding and disclosed that it still has cash-exercisable warrants for about 1.5 million shares, all with exercise prices of $7.00 or more per share, a development that clarifies its capitalization and potential future equity inflows for investors.

The company also highlighted that several recent Schedule 13G filings do not reflect the 1-for-4 reverse stock split completed on January 29, 2026, which means reported beneficial ownership stakes may appear overstated on a pre-split basis. Bluejay urged investors to account for this discrepancy when interpreting such filings, underscoring the importance of adjusted share counts in assessing ownership levels and market float following its capital structure changes.

The most recent analyst rating on (BJDX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Bluejay Advances SYMON II Sepsis Study and Manufacturing

On February 17, 2026, Bluejay Diagnostics reported significant progress in its SYMON II multicenter IL-6 monitoring study for sepsis, having enrolled 545 patients toward a 750-patient target under approved IRB protocols. Management said the growing, diverse dataset should strengthen its regulatory case and reduce clinical execution risk as the program moves from enrollment to data analysis and regulatory engagement.

The company also detailed advances in manufacturing readiness, including completion of cartridge characterization for U.S. commercial production and antibody production sufficient for over 10 million test cartridges. Ongoing work on cartridge fabrication, validation, and material substitutions, alongside a parallel, no–single point of failure technology transfer strategy, positions Bluejay in early 2026 with reduced execution risk and greater focus on commercialization preparedness.

The most recent analyst rating on (BJDX) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Bluejay Diagnostics Completes 1-for-4 Reverse Stock Split

On June 18, 2025, stockholders of Bluejay Diagnostics approved an amendment to the company’s charter to permit a reverse stock split at ratios between 1-for-2 and 1-for-20, and on January 27, 2026 the board selected a 1-for-4 ratio, filing a certificate of amendment in Delaware to implement the move. The 1-for-4 reverse stock split took effect at 12:01 a.m. Eastern Time on January 29, 2026, after which Bluejay’s common stock began trading on Nasdaq on a post-split basis under the unchanged ticker “BJDX” but with a new CUSIP, consolidating every four outstanding shares into one and cutting the share count from about 2,834,133 to roughly 708,533, with prefunded warrant shares and all equity awards and warrants adjusted proportionately. The reverse split, which leaves par value and voting rights intact and treats all stockholders uniformly, is operationally significant because it sharply reduces the number of shares outstanding while preserving ownership percentages, and it streamlines the capital structure for investors and warrant holders, who will see automatic adjustments in book-entry and street-name accounts and receive cash in lieu of fractional shares.

The most recent analyst rating on (BJDX) stock is a Hold with a $0.87 price target. To see the full list of analyst forecasts on Bluejay Diagnostics stock, see the BJDX Stock Forecast page.

Bluejay Diagnostics Scales IL-6 Antibody Production Capacity

On December 29, 2025, Bluejay Diagnostics announced it had completed commercial-scale production of both polyclonal and monoclonal antibodies targeting interleukin-6 (IL-6), a key biomarker for inflammatory and critical-care applications, with both antibody types meeting internal performance criteria for use in Symphony cartridge manufacturing. Internal testing showed acceptable binding, specificity and signal performance for the monoclonal detection antibodies, and the company now estimates its IL-6 antibody inventory could support production of more than nine million Symphony cartridges while also having the capability to produce additional antibodies, marking a significant operational milestone for scaling the Symphony platform even as the system remains under development and subject to further validation and regulatory review.